- Details
- Arun Azad discusses the LIBERTAS trial focusing on metastatic hormone-sensitive prostate cancer treatment with ADT plus apalutamide. The trial, aimed at improving patient outcomes and quality of life, explores the efficacy of deescalating therapy for patients achieving a PSA of less than 0.2 nanograms per milliliter after six months. The study includes a diverse patient population, irrespective of...
|
- Details
- Zach Klaassen and Peter Goebell discuss a systematic review focused on treatment intensification for metastatic hormone-sensitive prostate cancer. The study aims to assess if scientific evidence, as outlined in guidelines, translates into real-world practice changes. The review, incorporating data from 344,000 patients globally, examines the application of doublets and triplets in treatment, revea...
|
- Details
- Benjamin Lowentritt discusses metastatic hormone-sensitive prostate cancer (mHSPC) patients' responses to ADT combined with enzalutamide or apalutamide. Dr. Lowentritt explains the study's methodology, emphasizing the importance of a deep and quick PSA response as a positive outcome marker. Initial findings suggest a faster and more prevalent PSA90 response in patients treated with apalutamide com...
|
- Details
- Zach Klaassen converses with Daniel Saltzstein about the collaborative approach to treating metastatic hormone-sensitive prostate cancer with triplet therapy or maximum androgen blockade. Dr. Saltzstein describes their unique practice set up in San Antonio, where a medical oncologist is part of their urology team. This shared patient focus facilitates seamless collaboration and treatment managemen...
|
- Details
- Zach Klaassen is joined by Chandler Park and Ryan Malone to explore the collaborative approach between GU medical oncology and urology in managing metastatic hormone-sensitive prostate cancer with triplet therapy. Drs. Park and Malone, who met through shared patients and conferences, emphasize the importance of co-management in treating these complex cases. They discuss patient selection for tripl...
|
- Details
- Zach Klaassen engages with Vahan Kassabian and Sreekanth to discuss the continuum of care for patients with metastatic hormone-sensitive prostate cancer, particularly in the context of triplet therapy based on the ARASENS data. The conversation reveals their longstanding professional relationship, developed through mutual patients and a shared interest in urological oncology. They discuss the logi...
|
- Details
- Alicia Morgans hosts a multidisciplinary discussion with David Morris and Benjamin Garmezy focusing on the treatment of newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC). Dr. Morris highlights the increasing trend of referring patients with high-volume Gleason 8 disease and metastatic cancer to tertiary care centers. He emphasizes the importance of early discussions about intens...
|
- Details
- Rashid Sayyid and Zach Klaassen discuss the amended AUA guidelines for advanced prostate cancer, focusing on triplet therapy for metastatic hormone-sensitive prostate cancer (mHSPC) and non-metastatic castrate-resistant prostate cancer (M0 CRPC). They delve into the role of triplet therapy in mHSPC, examining its benefits across disease volume and risk subgroups, as evidenced by the ARASENS and PE...
|
- Details
- Dingwei Ye introduces a conversation with Alicia Morgans, featuring insights from Professor Yao Zhu, Deputy Executive Director of Urology Surgery at Fudan University Shanghai Cancer Center, on the recent findings from the ARASENS study in the Chinese population. Professor Zhu shares that the study included 202 Chinese patients, about one-seventh of the total, revealing significant efficacy of daro...
|
- Details
- Alicia Morgans speaks with Yong YANG about prostate cancer in China, focusing on the ARASENS Phase 3 Clinical Trial. Professor YANG reveals that prostate cancer incidence in China is about 12 per 10,000, with a lower five-year survival rate than in the USA, largely due to late diagnoses. Approximately 60% of patients initially presented with metastasis. Treatment follows international guidelines a...
|
